Helminthiasis
Drug research and approvals for helminthiasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 21 studies of helminthiasis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 21
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in EthiopiaNCT07948395 · Phase 2 / Phase 3 · University of Aarhus · starts Oct 10, 2026
- Collection of Biological Samples From Patients With Echinococcosis and Implementation of a Home-made PCR MethodNCT07715435 · Not reported · Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria · starts Aug 19, 2024
- Expanding Access to Preventive Chemotherapy Among Mobile and Migrant PopulationsNCT07707817 · Not applicable · Uwemedimo Friday Ekpo · starts Jul 1, 2026
- MATCHING - feMAle geniTal sCHistosomiasis IN miGrants Female Genital Schistosomiasis in Migrants Presenting to an…NCT07484256 · Not applicable · IRCCS Sacro Cuore Don Calabria di Negrar · starts Feb 20, 2025
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
- IM Bands in Inactive Hepatic CENCT07333612 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Sep 23, 2025
- Better Options for Lymphatic Filariasis TreatmentNCT07159373 · Phase 3 · Medicines Development for Global Health · starts Sep 28, 2026
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical…NCT07145736 · Phase 4 · Kirby Institute · starts Aug 4, 2025
- Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and PraziquantelNCT07074444 · Not applicable · First Affiliated Hospital of Guangxi Medical University · starts Jul 22, 2025
Approved 14
- AlbendazoleTubulin inhibitor
- MebendazoleTubulin inhibitor
- Bithionol
- LevamisoleNicotinic acetylcholine receptor alpha subunit agonist
- Piperazine
- DiethylcarbamazineNematode GABA-A receptor positive modulator
- ThiabendazoleTubulin inhibitor
- IvermectinGlutamate-gated chloride channel modulator
- NiclosamideDNA inhibitor
- OxamniquineDNA inhibitor
- Moxidectin
- Triclabendazole
- TrichlorfonAcetylcholinesterase 1 inhibitor
- Pyrantel
Phase 3 1
Phase 2 8
- OxfendazoleTubulin inhibitor
- FenbendazoleTubulin beta chain binding agent
- Niridazole
- Cyclobendazole
- Dichlorophen
- Flubendazole
- Desaspidin
- Oxantel
Phase 1 or earlier 1
How its trials ended
71 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 20 whose ending is known, 40% met their primary endpoint, 20% missed it and 40% stopped early.
- Completed, result not reported3346%
- Ongoing1217%
- Met its primary endpoint811%
- Status unknown68%
- Stopped: other or unclear57%
- Missed its primary endpoint46%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA